Breaking News Instant updates and real-time market news.

REGN

Regeneron

$377.80

-6.4 (-1.67%)

, SNY

Sanofi

$43.45

0.56 (1.31%)

05:30
10/16/18
10/16
05:30
10/16/18
05:30

Regeneron, Sanofi announce Phse 3 Dupixent trials met all endpoints

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that both pivotal Phase 3 placebo-controlled trials evaluating Dupixent in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps, met all their primary and secondary endpoints. On the co-primary endpoints for both trials at 24 weeks, patients treated with Dupixent added to a standard-of-care corticosteroid nasal spray experienced a 51% and 57% improvement in their nasal congestion/obstruction severity compared to a 15% and 19% improvement with nasal spray alone. Dupixent-treated patients had a 27% and 33% reduction in their nasal polyps score compared to a 4% and 7% increase for placebo. Dupixent also met all secondary endpoints in both trials, including demonstrating a significant reduction in the need for systemic corticosteroids or surgery, and improvements in smell and chronic rhinosinusitis symptoms. In a pre-specified group of patients with comorbid asthma, Dupixent significantly improved lung function and asthma control. Dupixent blocks the IL-4 and IL-13 signaling pathways.

REGN

Regeneron

$377.80

-6.4 (-1.67%)

SNY

Sanofi

$43.45

0.56 (1.31%)

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

REGN Regeneron
$377.80

-6.4 (-1.67%)

10/11/18
PIPR
10/11/18
NO CHANGE
Target $450
PIPR
Overweight
Piper remains buyer of Regeneron ahead of October 20 FDA action date
Piper Jaffray analyst Christopher Raymond says he remains a buyer of Regeneron Pharmaceuticals (REGN) ahead of the Dupixent asthma October 20 FDA action date. With consensus expecting this indication to contribute well over $1B in revenue in coming years, approval is a "critical near-term catalyst" for the shares, Raymond tells investors in a research note. The analyst adds that while some investors have expressed angst over the breadth of the label, namely restricting use to eosinophilic asthma, he believes recent Sanofi (SNY) commentary provides reason for optimism. The totality of clinical data and the biology behind Dupixent supports a broad label, Raymond contends. He maintains an Overweight rating on Regeneron with a $450 price target.
10/01/18
LEER
10/01/18
NO CHANGE
Target $512
LEER
Outperform
Regeneron price target raised to $512 from $506 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Regeneron to $512 from $506 after the FDA approved the jointly developed and commercialized REGN/SNY PD-1 antibody cemiplimab, now known as Libtayo. The analyst reiterates an Outperform rating on the shares.
10/01/18
CANT
10/01/18
INITIATION
Target $415
CANT
Neutral
Regeneron initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Regeneron Pharmaceuticals with a Neutral rating and $415 price target.
10/01/18
PIPR
10/01/18
NO CHANGE
PIPR
Overweight
Piper keeps Overweight on Regeneron after Libtayo approval
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals (REGN) after Friday's FDA approval of Libtayo in cutaneous squamous cell carcinoma. Timing is about a month ahead of the late-October FDA action date for Regeneron/Sanofi's (SNY) PD-1 inhibitor, but a positive decision was expected given the drug's "compelling data" in advanced CSCC, Raymond tells investors in a research note. While Libtayo will enter the market as the sixth approved PD-(L)1 inhibitor and third approved PD-1 agent, Raymond thinks readouts from the ongoing development program in other indications such as first-line non-small-cell lung carcinoma may make the case for moderate Libtayo uptake. However, he continues to like the set-up for Regeneron shares going forward.
SNY Sanofi
$43.45

0.56 (1.31%)

10/09/18
BARD
10/09/18
INITIATION
Target $50
BARD
Outperform
Principia Biopharma initiated with an Outperform at Baird
Baird analyst Brian Skorney started Principia Biopharma (PRNB) with an Outperform rating and $50 price target, stating that its BTK inhibitor partnered with Sanofi (SNY) for multiple sclerosis has blockbuster potential. He also believes PRN1008, which is entering Phase 3, has a worldwide opportunity over $500M in pemphigus that would also open the door for a host of other indications.
10/08/18
GUGG
10/08/18
INITIATION
GUGG
Neutral
Sanofi initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started Sanofi with a Neutral rating and EUR83 price target. He sees its low earnings risk, strong dividend, and reasonable valuation being offset by competitive intensity building for Dupixent and its hemophilia franchises.

TODAY'S FREE FLY STORIES

CAL

Caleres

$25.84

-1.3 (-4.79%)

, EMR

Emerson

$68.45

-0.32 (-0.47%)

07:13
03/20/19
03/20
07:13
03/20/19
07:13
Hot Stocks
Caleres elects Emerson CCO Lisa Flavin to board of directors »

Caleres (CAL) announced…

CAL

Caleres

$25.84

-1.3 (-4.79%)

EMR

Emerson

$68.45

-0.32 (-0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 07

    May

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

07:12
03/20/19
03/20
07:12
03/20/19
07:12
Recommendations
Smartsheet analyst commentary  »

Smartsheet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Apr

SSP

E.W. Scripps

$22.47

0.05 (0.22%)

, NXST

Nexstar

$105.71

-0.85 (-0.80%)

07:12
03/20/19
03/20
07:12
03/20/19
07:12
Hot Stocks
E.W. Scripps acquiring eight TV stations from Nexstar-Tribune merger divestiture »

E.W. Scripps (SSP) is…

SSP

E.W. Scripps

$22.47

0.05 (0.22%)

NXST

Nexstar

$105.71

-0.85 (-0.80%)

TRCO

Tribune Media

$46.08

0.02 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$47.24

-0.365 (-0.77%)

07:11
03/20/19
03/20
07:11
03/20/19
07:11
Hot Stocks
Breaking Hot Stocks news story on General Mills »

General Mills up 6.4% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

LULU

Lululemon

$144.95

0.61 (0.42%)

07:11
03/20/19
03/20
07:11
03/20/19
07:11
Recommendations
Lululemon analyst commentary  »

Barclays remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

ALXN

Alexion

$132.94

-0.53 (-0.40%)

, ZEAL

Zealand Pharma

$15.60

(0.00%)

07:11
03/20/19
03/20
07:11
03/20/19
07:11
Hot Stocks
Alexion, Zealand Pharma announce collaboration for peptide therapies »

Alexion Pharmaceuticals…

ALXN

Alexion

$132.94

-0.53 (-0.40%)

ZEAL

Zealand Pharma

$15.60

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 28

    Jun

GIS

General Mills

$47.24

-0.365 (-0.77%)

07:10
03/20/19
03/20
07:10
03/20/19
07:10
Hot Stocks
General Mills sees FY19 adjusted operating profit at high end of 6%-9% growth »

Constant-currency…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

07:10
03/20/19
03/20
07:10
03/20/19
07:10
General news
FX Update: The dollar has traded steady-to-firmer »

FX Update: The dollar has…

NTNX

Nutanix

$38.78

0.425 (1.11%)

07:09
03/20/19
03/20
07:09
03/20/19
07:09
Conference/Events
Nutanix to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

  • 04

    Apr

  • 09

    Jul

TGNA

Tegna

$14.42

-0.2 (-1.37%)

, NXST

Nexstar

$105.71

-0.85 (-0.80%)

07:09
03/20/19
03/20
07:09
03/20/19
07:09
Hot Stocks
TEGNA to acquire 11 local television stations from Nexstar for $740M »

TEGNA (TGNA) announced…

TGNA

Tegna

$14.42

-0.2 (-1.37%)

NXST

Nexstar

$105.71

-0.85 (-0.80%)

TRCO

Tribune Media

$46.08

0.02 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

, GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

07:08
03/20/19
03/20
07:08
03/20/19
07:08
Recommendations
Alphabet, Alphabet Class A, Sony, Microsoft, Amazon.com analyst commentary  »

Google's Stadia…

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

SNE

Sony

$45.50

-0.595 (-1.29%)

MSFT

Microsoft

$117.72

0.12 (0.10%)

AMZN

Amazon.com

$1,762.45

20.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 26

    Mar

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

AIR

AAR Corp.

$35.10

(0.00%)

07:08
03/20/19
03/20
07:08
03/20/19
07:08
Recommendations
AAR Corp. analyst commentary  »

AAR Corp. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEUM

Pareteum

$5.04

-0.67 (-11.73%)

, CTXS

Citrix

$101.31

-0.24 (-0.24%)

07:08
03/20/19
03/20
07:08
03/20/19
07:08
Hot Stocks
Pareteum's iPass SmartConnect solution selected for Citrix »

Pareteum (TEUM) announced…

TEUM

Pareteum

$5.04

-0.67 (-11.73%)

CTXS

Citrix

$101.31

-0.24 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 17

    Apr

  • 28

    May

RTIX

RTI Surgical

$5.88

-0.08 (-1.34%)

07:08
03/20/19
03/20
07:08
03/20/19
07:08
Hot Stocks
RTI Surgical enrolls first patient in FORTE study »

RTI Surgical announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

  • 28

    May

GIS

General Mills

$47.24

-0.365 (-0.77%)

07:08
03/20/19
03/20
07:08
03/20/19
07:08
Hot Stocks
General Mills CEO confident in meeting, exceeding all FY19 targets »

"We had a strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

CREE

Cree

$57.27

0.36 (0.63%)

07:07
03/20/19
03/20
07:07
03/20/19
07:07
Upgrade
Cree rating change  »

Cree upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

BHC

Bausch Health

$26.29

1.745 (7.11%)

07:07
03/20/19
03/20
07:07
03/20/19
07:07
Initiation
Bausch Health initiated  »

Bausch Health initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VERI

Veritone

$6.34

-0.155 (-2.39%)

07:07
03/20/19
03/20
07:07
03/20/19
07:07
Conference/Events
Veritone to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

GIS

General Mills

$47.24

-0.365 (-0.77%)

07:06
03/20/19
03/20
07:06
03/20/19
07:06
Hot Stocks
General Mills expects Q4 Blue Buffalo's net sales to 'accelerate meaningfully' »

For the fourth quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

NXST

Nexstar

$105.71

-0.85 (-0.80%)

, TRCO

Tribune Media

$46.08

0.02 (0.04%)

07:06
03/20/19
03/20
07:06
03/20/19
07:06
Hot Stocks
Nexstar expects Tribune deal to result in 46% growth to average annual FCF »

Nexstar (NXST) CEO Perry…

NXST

Nexstar

$105.71

-0.85 (-0.80%)

TRCO

Tribune Media

$46.08

0.02 (0.04%)

TGNA

Tegna

$14.42

-0.2 (-1.37%)

SSP

E.W. Scripps

$22.47

0.05 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

MDR

McDermott

$7.62

-0.285 (-3.61%)

07:06
03/20/19
03/20
07:06
03/20/19
07:06
Hot Stocks
McDermott awarded ethylene contract in Russia »

McDermott has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

FDX

FedEx

$181.50

-0.92 (-0.50%)

07:06
03/20/19
03/20
07:06
03/20/19
07:06
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Apr

  • 02

    Apr

  • 25

    Jun

GIS

General Mills

$47.24

-0.365 (-0.77%)

07:05
03/20/19
03/20
07:05
03/20/19
07:05
Hot Stocks
General Mills sees FY19 free cash flow conversion of at least 105% »

The company now expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

KALV

KalVista

$28.35

2.05 (7.79%)

07:05
03/20/19
03/20
07:05
03/20/19
07:05
Initiation
KalVista initiated  »

KalVista initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOLD

Amicus

$13.45

-0.09 (-0.66%)

07:05
03/20/19
03/20
07:05
03/20/19
07:05
Hot Stocks
Amicus issued two patents for ATB200 from USPTO »

Amicus announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.